Bristol-Myers Squibb: Unlocking Value With KarXT FDA Approval And Oncology Pipeline Progress
…
59,602$
-3,45%
Echtzeit-Aktienkurs Bristol-Myers Squibb Co.
Bid:
Ask:
Nachrichten zur Bristol-Myers Squibb Co. Aktie
Bristol Myers Squibb shares move higher on FDA approval of schizophrenia drug
Bristol Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP) shares moved higher after the pharmaceutical company’s schizophrenia drug was approved by the…
US drug regulator approves the first new schizophrenia drug in 30 years
The US Food and Drug Administration (FDA) has approved Cobenfy, the first new drug for schizophrenia in over 30 years, developed…
FDA approves Bristol Myers Squibbs schizophrenia drug, the first new type of treatment in decades
The twice-daily pill, Cobenfy, is a badly needed new treatment option for the nearly 3 million adults in the U.S.…
Bristol-Myers Squibb Aktie: Spannung vor FDA-Entscheidung zu KarXT
Die Spannung steigt bei Bristol-Myers Squibb (BMY) vor der anstehenden FDA-Entscheidung zum Schizophrenie-Medikament KarXT am 26. September. Das innovative Präparat,…
Drugmakers bet billions that targeted radiation could become the next cancer breakthrough
Bristol Myers Squibb, AstraZeneca, Eli Lilly and other drug companies have invested some $10 billion on promising cancer technology behind…
Bristol-Myers Squibb Company PFD CONV 2 declares $0.50 dividend
…
Bristol-Myers Squibb declares $0.60 dividend
…
Bristol Myers Squibb: Momentum Still Promising Through H2 2024, Turnaround Likely Prolonged
…
Bristol-Myers Squibb: Shares Getting Closer To The Tipping Point (Rating Downgrade)
…
Bristol-Myers Squibb: A Better Earnings Outlook, Stronger Momentum Heading Into 2025
…
Bristol-Myers Squibb Company (BMY) Wells Fargo 2024 Healthcare Conference (Transcript)
…
Global Hematologic Malignancies Market Size To Worth USD 144.58 Billion By 2033 | CAGR Of 7.97%
The Global Hematologic Malignancies Market Size was Valued at USD 67.18 Billion in 2023 and the Worldwide Hematologic Malignancies Market…
Bristol-Myers Squibb Company (BMY) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
…
2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High
Rebounding growth could make shares of this leading drugmaker a big winner.…
2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High
…
How To Put $100 In Your Retirement Fund Each Month With Bristol-Myers Squibb Stock
…
Bristol-Myers Squibb-backed Zenas BioPharma files for US IPO By Reuters
Bristol-Myers Squibb-backed Zenas BioPharma files for US IPO…
Billion-dollar Deals in Radiopharmaceuticals Catch Investor Attention
Recent mergers and acquisitions and partnership deals in the medical industry are showing signs of increasing investor interest in the…
Where Will Bristol Myers Squibb Be in 5 Years?
The drugmaker will go through key changes by the end of the decade.…
Evotec: Diese Zahlung von Bristol Myers Squibb treibt die Aktie an
Evotec erhält 75 Millionen Dollar von Bristol Myers Squibb für Fortschritte in der Krebsforschung.…
Evotec erhält 75 Millionen Dollar Meilensteinzahlung von Bristol Myers Squibb
HAMBURG (dpa-AFX) - Evotec hat in seiner Partnerschaft mit dem US-Pharmaunternehmen Bristol-Myers Squibb Fortschritte erzielt und so Meilensteinzahlungen…
EQS-News: Evotec verkündet starke Fortschritte in strategischer Partnerschaft mit Bristol Myers Squibb im Bereich Protein Degradation (deutsch)
Evotec verkündet starke Fortschritte in strategischer Partnerschaft mit Bristol Myers Squibb im Bereich Protein Degradation^EQS-News: Evotec SE / Schlagwort(e): SonstigesEvotec…
EQS-News: Evotec verkündet Fortschritt in strategischer Neurologie-Partnerschaft mit Bristol Myers Squibb (deutsch)
Evotec verkündet Fortschritt in strategischer Neurologie-Partnerschaft mit Bristol Myers Squibb^EQS-News: Evotec SE / Schlagwort(e): SonstigesEvotec verkündet Fortschritt in strategischer Neurologie-Partnerschaft…
Bristol-Myers Squibb: A Potential Comeback In Healthcare
…
Albumin-gebundenes Paclitaxel von Kexing Biopharm erhält EU-Marktzulassung
Kexing Biopharm: Shenzhen, China (ots/PRNewswire) - Am 28. Juli 2024 gab Kexing Biopharm die Genehmigung der Europäischen Kommission für Apexelsin®…
Analyst Report: Bristol-Myers Squibb Co.
…
Is Bristol Myers Squibb a Good Dividend Stock to Buy Now?
A lowered outlook for 2024 and upcoming patent expirations have investors concerned about this pharmaceutical giants dividend program.…
Is Bristol Myers Squibb a Good Dividend Stock to Buy Now? @themotleyfool #stocks $BMY $PFE
A lowered outlook for 2024 and upcoming patent expirations have investors concerned about this pharmaceutical giants dividend program.…
Bristol-Myers Squibb Earnings Reinforces Our Thesis
…
Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point
…
Why Bristol Myers Squibb Jumped Nearly 10% on Friday
The pharmaceutical company is faring far better than most investors were anticipating at this point.…
Why Bristol Myers Squibb Jumped Nearly 10% on Friday
…
Why Bristol Myers Squibb Jumped Nearly 10% on Friday @themotleyfool #stocks $BMY
The pharmaceutical company is faring far better than most investors were anticipating at this point.…
Bristol Myers Squibb (BMY) Q2 2024 Earnings Call Transcript
BMY earnings call for the period ending June 30, 2024.…
Bristol Myers Squibb Witnesses Strong Demand For Newer Drugs As Q2 Earnings Beat Expectations, Raises 2024 Profit Forecast
…
Bristol-Myers Squibb stock gains after raising full-year guidance By Investing.com
Bristol-Myers Squibb stock gains after raising full-year guidance…
Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs
The results come as Bristol Myers moves to cut $1.5 billion in costs by 2025 and reinvest that money into…
June PCE, Bristol Myers Squibb earnings: What to watch Friday
Asking for a Trend Host Josh Lipton breaks down what to watch on Friday, July 26th. Personal Consumption Expenditures (PCE)…
Global Musculoskeletal Market Size is Expected To Hold a Significant Share By 2033 | CAGR of 6.2%
The Market Size is Growing at a Substantial CAGR of 6.2% from 2023 to 2033 and the Worldwide Musculoskeletal Market…
NCLA Asks Third Circuit to Rule Against HHS’s Coercive Medicare Drug Price ‘Negotiation’ Program
Bristol Myers Squibb Company, et al. v. Xavier Becerra, et al. Bristol Myers Squibb Company, et al. v. Xavier Becerra,…
Bristol-Myers Squibb - Investors Are Too Long-Term Focused (NYSE:BMY)
Bristol-Myers Squibb faces challenges with patent expirations, but has long-term shareholder return potential. Read why BMY stock is a good investment.…
Bristol-Myers Squibb Is A Bargain Now
…
Is Bristol-Myers Squibbs Rich Dividend Yield Worth The Patent Cliff Correction Risk?
…
Bristol-Myers Squibb: Seriously Undervalued And Poised For An Inflection
…
Erste Schätzungen: Bristol-Myers Squibb vermeldet Zahlen zum jüngsten Quartal
Bristol-Myers Squibb wird voraussichtlich am 26.07.2024 in der Finanzkonferenz die Quartalszahlen zum jüngsten Jahresviertel – Abschlussdatum 30.06.2024 – vorstellen.Die Schätzungen…
Bristol-Myers Squibb: Time To Double Down
…
Is Bristol Myers Squibb Stock a Buy?
Does Bristol Myers have the potential to be a market-beating stock?…
Is Bristol Myers Squibb Stock a Buy? @themotleyfool #stocks $BMY
Does Bristol Myers have the potential to be a market-beating stock?…
Global Lenalidomide Drug Market Size To Worth USD 21.47 Billion By 2033 | CAGR Of 5.69%
The Global Lenalidomide Drug Market Size was Valued at USD 12.34 Billion in 2023 and the Worldwide Lenalidomide Drug Market…